On Sunday, Dr. Brian Wolpin of the Dana-Farber Cancer Institute presented data on pancreatic cancer that is moving the field ...

Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...

FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...

RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...

The results of the survey revealed that the growing direct-to-patient approach is having a significant impact on how ...

Enforcement starts with June 1 notices giving select covered entities five business days to submit required claims data or lose access to 340B pricing, with additional entities targeted imminently.

HHS Secretary Kennedy has also highlighted his concerns with DTC prescription drug advertisements. At the time of the ...

A wave of expiries will hit high-value assets, including Keytruda, Eliquis, Ibrance, and Trulicity, amplifying revenue ...

In today's Pharmaceutical Executive Daily, Cam Olig of Prescryptive Health touches on the results of a new market access survey, Eli Lilly and Ascidian Therapeutics announce a global research ...

A trio of deals from Eli Lilly, Servier, and Avenzo highlights continued industry investment in rare diseases and oncology, ...

FDA’s CRL focused on CMC deficiencies, with no objections to clinical safety or efficacy, enabling a resubmission pathway primarily driven by manufacturing remediation. The NDA was accepted in October ...

FDA approves Gilead’s Hepcludex as the first treatment for chronic hepatitis delta virus in the U.S., marking a major ...